Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40

Targeted and immune-based therapies are thought to eradicate cancer cells by different mechanisms, and these approaches could possibly complement each other when used in combination. In this study, we report that the in vivo antitumor effects of the c-KIT inhibitor, dasatinib, on the c-KIT mutant P8...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yang, Yan, Liu, Chengwen, Peng, Weiyi, Lizée, Gregory, Overwijk, Willem W., Liu, Yang, Woodman, Scott E., Hwu, Patrick
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Immunobiology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3512233/
https://ncbi.nlm.nih.gov/pubmed/22936666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-407163
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak